pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,053 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT776Endpoints579BioPharma Dive223onclive165Fierce Biotech54BioSpace52raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • Biotech industry leaders file brief backing FDA against ‘malicious’ mifepristone challenge
    A group of 61 biopharma companies, executives and investors has filed an amicus brief in support of the FDA in an ongoing case brought by Louisiana meant to remove access to the abortion pill mifep…
    Fierce Biotech · 3d ago↗ source
  • Agios scraps sickle cell drug
    <figure><div><img src="https://imgproxy.divecdn.com/IiZTvtDA9eY9PoU6z9Ed0haIV_AWxuu_mTZM3XObZMk/g:nowe:0:88/c:4896:2766/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy…
    BioPharma Dive · 3d ago↗ source
  • Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs
    <figure><div><img src="https://imgproxy.divecdn.com/kw1AmHZ9iuWuwJs64qGVc7NH8w1twh5k8aIFqw3zDIg/g:nowe:0:388/c:5567:3145/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlc…
← prev
page 4 of 43
next →
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
BioPharma Dive · 3d ago↗ source
  • Opinion: Pete Hegseth, ‘The Odyssey,’ and the testosterone myth
    The poet didn’t say “sing to me, Muse, of a man with optimized endocrine panels," writes urologist Elizabeth Dray.
    STAT · 3d ago↗ source
  • Dimension restocks with $800M to capitalize on AI’s ‘rapid ascent’
    <p>The young venture firm, which has bet heavily on tech and biotech’s convergence, has now invested in 35 companies and recently saw one of them acquired by AI giant Anthropic.</p>
    BioPharma Dive · 3d ago↗ source
  • Novartis climbs on upbeat drug sales as key readouts loom
    <figure><div><img src="https://imgproxy.divecdn.com/zfRhQ6UdoLhrnrg6WnOJHxS_autlpVcZwuWId9Q7ZSI/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMjA5Nzg4MDE4LmpwZ…
    BioPharma Dive · 3d ago↗ source
  • STAT+: Advocates say federal funding is being cut from groups fighting HIV
    The administration is shifting some funding to states, but community groups are set to lose out.
    STAT · 3d ago↗ source
  • Crystalys mines $130M series B to push gout drug through phase 3
    Crystalys Therapeutics has raised $130 million in series B financing to advance the development of its gout drug dotinurad and prepare for a potential commercial launch.<br>
    Fierce Biotech · 3d ago↗ source
  • Is there an exodus underway at Epic?
    In this edition of STAT Health Tech: executive departures at Epic Systems, new CEO takes over at Nabla, and more health tech news.
    STAT · 3d ago↗ source
  • STAT+: Broad Institute, partners unveil new initiative to develop gene therapies for rare diseases
    The Broad Institute, Boston Children’s Hospital, and Maine’s Jackson Laboratory announced a collaboration to develop rare disease gene therapies.
    STAT · 3d ago↗ source
  • STAT+: Anthropic deepens work with rare disease drugs
    Novo Nordisk sues Eli Lilly over GLP-1s, Medicare pricing plans, and more biotech news from The Readout
    STAT · 3d ago↗ source
  • STAT+: Pharmalittle: We’re reading about Novo suing Lilly over ‘deceptive’ ads, a fugitive’s secret life in biotech, and more
    Novo Nordisk sued Eli Lilly for allegedly running “deceptive” ads to make its obesity and diabetes drugs appear more effective
    STAT · 3d ago↗ source
  • ‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx deal
    For years, as Big Pharma poured billions into ADCs, Novartis CEO Vas Narasimhan notably stayed on the sidelines. Asked by Fierce during Novartis’ Q2 earnings call, Narasimhan explained why he is en…
    Fierce Biotech · 3d ago↗ source
  • STAT+: Nabla’s new CEO on plan to gain market share in a competitive AI scribe environment
    Ambient scribe developer Nabla said Brian Manning will be the Paris-based company's new CEO as it looks to grow in a highly competitive market.
    STAT · 3d ago↗ source
  • STAT+: Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’
    Novo Nordisk sued Eli Lilly for allegedly running a “deceptive” ad campaign that uses “outdated clinical trials” to make its obesity and diabetes drugs appear more effective.
    STAT · 3d ago↗ source
  • A renewed push from the right against abortion pills
    The latest on cyclospora, THC sodas at the grocery store, and more health news from Morning Rounds
    STAT · 3d ago↗ source
  • Jupiter enters psychedelics space with $100M deal for PharmAla's MDMA drug
    Jupiter Neurosciences will pay $3.3 million upfront to Canada's PharmAla Biotech for U.S. rights to an MDMA drug to treat neuropsychiatric disorders.
    Fierce Biotech · 3d ago↗ source
  • THC drinks are sold beside sodas, iced tea, and even chocolate milk, often in violation of state laws
    THC drinks, which have exploded in popularity in recent years, are sold in retail stores beside sodas, iced tea, and even chocolate milk, often in violation of state laws.
    STAT · 3d ago↗ source
  • Opinion: How a controversial rule could hurt the NIH’s ability to manage risk
    The proposed rule could “weaken the NIH’s benign influence over research risks,” writes Doni Bloomfield.
    STAT · 3d ago↗ source
  • Opinion: Science and the public are learning the wrong lessons from Covid
    “Post-pandemic polarization threatens to lock our memories into attractive, untrue conclusions that will leave us unprotected next time,” write Marc Lipsitch and Sara Cody.
    STAT · 3d ago↗ source
  • STAT+: Makers of rare disease drugs seek exemption from Trump’s price-cut pilots
    A coalition of biotech firms is lobbying to exclude orphan drugs from new federal pilot programs aimed at lowering Medicare drug costs.
    STAT · 3d ago↗ source
  • Agios says adios to sickle cell program over lackluster phase 2 data
    A phase 2 study of Agios Pharmaceuticals’ next-generation pyruvate kinase activator has failed to support continued development in sickle cell disease, leading the company to ax an indication for t…
    Fierce Biotech · 3d ago↗ source
  • Novartis drops phase 2 radioligand therapy, but CEO’s commitment to modality ‘unchanged’
    Novartis has dropped a phase 2-stage radioligand therapy after the candidate disappointed in the clinic.
    Fierce Biotech · 3d ago↗ source
  • Indian generics maker Lupin seeds US spinout Kaveri with cash, clinical-phase cancer assets
    Lupin has spun out two clinical-phase cancer drug candidates to create Kaveri Therapeutics, a U.S.-based startup that plans to raise cash for further development. Kaveri’s programs hit targets purs…
    Fierce Biotech · 3d ago↗ source
  • Roche taps Foundation Medicine’s chief as new North America Diagnostics lead, creates new commercial role
    Dan Malarek is leaving his role as chief executive of Roche’s sequencing subsidiary Foundation Medicine as he takes up the mantle as President and CEO of Roche Diagnostics North America.
    Fierce Biotech · 4d ago↗ source